Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 379,500 shares, an increase of 600.2% from the March 31st total of 54,200 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 4.4% of the company’s stock are short sold.

Xilio Therapeutics Stock Up 7.9 %

Shares of XLO stock opened at $1.09 on Friday. The company has a 50 day moving average price of $0.92 and a 200-day moving average price of $1.03. Xilio Therapeutics has a 52 week low of $0.49 and a 52 week high of $3.40. The firm has a market capitalization of $37.57 million, a PE ratio of -0.39 and a beta of -0.12.

Xilio Therapeutics (NASDAQ:XLO) last announced its earnings results on Monday, April 1st. The company reported ($0.64) earnings per share (EPS) for the quarter. Analysts anticipate that Xilio Therapeutics will post -1.53 earnings per share for the current year.

Insider Buying and Selling at Xilio Therapeutics

In other news, major shareholder Gilead Sciences, Inc. acquired 485,250 shares of Xilio Therapeutics stock in a transaction on Tuesday, April 2nd. The stock was acquired at an average cost of $0.76 per share, for a total transaction of $368,790.00. Following the purchase, the insider now owns 7,345,473 shares in the company, valued at $5,582,559.48. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xilio Therapeutics

An institutional investor recently bought a new position in Xilio Therapeutics stock. PFG Investments LLC purchased a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned approximately 0.09% of Xilio Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.